DE69430315D1 - Methoden zur (ex vivo) therapie mittels peptid - bestueckten antigen - praesentierenden zellen zur aktivierung von ctl - Google Patents

Methoden zur (ex vivo) therapie mittels peptid - bestueckten antigen - praesentierenden zellen zur aktivierung von ctl

Info

Publication number
DE69430315D1
DE69430315D1 DE69430315T DE69430315T DE69430315D1 DE 69430315 D1 DE69430315 D1 DE 69430315D1 DE 69430315 T DE69430315 T DE 69430315T DE 69430315 T DE69430315 T DE 69430315T DE 69430315 D1 DE69430315 D1 DE 69430315D1
Authority
DE
Germany
Prior art keywords
peptide
vivo
therapy
methods
presenting cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69430315T
Other languages
English (en)
Other versions
DE69430315T2 (de
Inventor
Esteban Celis
Ralph Kubo
Horacio Serra
Van Tsai
Peggy Wentworth
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Epimmune Inc
Original Assignee
Epimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epimmune Inc filed Critical Epimmune Inc
Publication of DE69430315D1 publication Critical patent/DE69430315D1/de
Application granted granted Critical
Publication of DE69430315T2 publication Critical patent/DE69430315T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/464486—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69430315T 1993-08-06 1994-08-01 Methoden zur (ex vivo) therapie mittels peptid - bestueckten antigen - praesentierenden zellen zur aktivierung von ctl Expired - Lifetime DE69430315T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10340193A 1993-08-06 1993-08-06
PCT/US1994/008672 WO1995004817A1 (en) 1993-08-06 1994-08-01 Methods for ex vivo therapy using peptide-loaded antigen presenting cells for the activation of ctl

Publications (2)

Publication Number Publication Date
DE69430315D1 true DE69430315D1 (de) 2002-05-08
DE69430315T2 DE69430315T2 (de) 2002-11-21

Family

ID=22294982

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69430315T Expired - Lifetime DE69430315T2 (de) 1993-08-06 1994-08-01 Methoden zur (ex vivo) therapie mittels peptid - bestueckten antigen - praesentierenden zellen zur aktivierung von ctl

Country Status (7)

Country Link
US (1) US5846827A (de)
EP (1) EP0726941B1 (de)
AU (1) AU7478394A (de)
CA (1) CA2168950A1 (de)
DE (1) DE69430315T2 (de)
SG (1) SG49113A1 (de)
WO (1) WO1995004817A1 (de)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6607727B1 (en) 1991-08-26 2003-08-19 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepatitus B virus
US9340577B2 (en) 1992-08-07 2016-05-17 Epimmune Inc. HLA binding motifs and peptides and their uses
US5662907A (en) * 1992-08-07 1997-09-02 Cytel Corporation Induction of anti-tumor cytotoxic T lymphocytes in humans using synthetic peptide epitopes
US6235288B1 (en) 1992-08-26 2001-05-22 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepatitis B virus
KR960700745A (ko) * 1993-02-26 1996-02-24 더글라스 에이. 빙햄 비(b)형 간염 바이러스에 대한 세포독성 티(t) 임파세포 응답반응을 유도하는 펩티드(peptides for inducing cytotoxic t lymphocyte responses to hepatitis b virus)
EP0721341A4 (de) * 1993-08-06 1998-04-22 Cytel Corp Die klonierung und charakterisierung des vollständigen mage-1-gens
KR100235849B1 (ko) * 1993-10-19 1999-12-15 에가시라 구니오 HIV에 대한 면역응답을 유도할 수 있는 펩티드 및 그 펩티드를 함유하는 항 AIDS 예방, 치료제(Peptides Capable of Inducing Immune Response to HIV and Anti-AIDS Agent for Preventing and Curing AIDS)
US6682731B1 (en) * 1994-03-24 2004-01-27 Ludwig Institute For Cancer Research Isolated peptides derived from mage tumor rejection antigen precursors which complex with HLA-A2 molecules
US6300090B1 (en) * 1994-07-29 2001-10-09 The Rockefeller University Methods of use of viral vectors to deliver antigen to dendritic cells
US5587289A (en) * 1995-03-14 1996-12-24 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which are members of the MAGE-Xp family and uses thereof
AU7008896A (en) * 1995-08-21 1997-03-12 Duke University A method to increase the density of antigen on antigen presenting cells
ATE244300T1 (de) 1996-01-17 2003-07-15 Imp College Innovations Ltd Immunotherapie mit verwendung von zytotoxischen t lymphozyten (ctl)
US6346390B1 (en) * 1996-03-08 2002-02-12 Receptron, Inc. Receptor derived peptides involved in modulation of response to ligand binding
US6130087A (en) * 1996-10-07 2000-10-10 Fordham University Methods for generating cytotoxic T cells in vitro
US20050170503A1 (en) * 1997-02-27 2005-08-04 University Of Pittsburgh In vitro induction of antigen-specific T-cells using dendritic cell-tumor cell or dendritic cell-viral cell derived immunogens
WO1999058658A2 (en) * 1998-05-13 1999-11-18 Epimmune, Inc. Expression vectors for stimulating an immune response and methods of using the same
US7264965B2 (en) * 1998-06-05 2007-09-04 Alexis Biotech Limited Method for producing or enhancing a T-cell response against a target cell using a complex comprising an HLA class I molecule and an attaching means
US7521197B2 (en) * 1998-06-05 2009-04-21 Alexis Biotech Limited Method for producing cytotoxic T-cells
US7713739B1 (en) 2000-11-17 2010-05-11 Novartis Vaccines And Diagnostics, Inc. Microparticle-based transfection and activation of dendritic cells
US6897288B1 (en) * 1999-10-19 2005-05-24 Ludwig Institute For Cancer Research Mage-A12 antigenic peptides and uses thereof
US6602510B1 (en) 2000-04-05 2003-08-05 Epimmune Inc. HLA class I A2 tumor associated antigen peptides and vaccine compositions
US20070098776A1 (en) * 1999-12-13 2007-05-03 Fikes John D HLA class I A2 tumor associated antigen peptides and vaccine compositions
US20040248113A1 (en) * 1999-12-28 2004-12-09 Alessandro Sette Method and system for optimizing multi-epitope nucleic acid constructs and peptides encoded thereby
US7462354B2 (en) 1999-12-28 2008-12-09 Pharmexa Inc. Method and system for optimizing minigenes and peptides encoded thereby
IL155307A0 (en) * 2000-10-10 2003-11-23 Univ Oklahoma Methods for isolating, identifying and purifying peptide ligands and peptide ligands produced thereby
CA2438505A1 (en) * 2001-02-14 2002-09-12 Genzyme Corporation Altered peptide ligands
DE10109224A1 (de) * 2001-02-26 2002-09-05 Bayer Ag Flammwidrige Polycarbonat-Zusammensetzungen mit erhöhter Chemikalienbeständigkeit
FR2821947B1 (fr) * 2001-03-12 2003-05-16 Canon Kk Procede et dispositif de validation de parametres definissant une image
US20060222656A1 (en) * 2005-04-01 2006-10-05 University Of Maryland, Baltimore MAGE-A3/HPV 16 peptide vaccines for head and neck cancer
WO2002094994A2 (en) * 2001-05-18 2002-11-28 Mayo Foundation For Medical Education And Research Chimeric antigen-specific t cell-activating polypeptides
US20030134341A1 (en) * 2001-09-19 2003-07-17 Medcell Biologics, Llc. Th1 cell adoptive immunotherapy
US20030175242A1 (en) * 2001-09-17 2003-09-18 Micheal Gruenberg Cell therapy system
US20030134415A1 (en) * 2001-09-19 2003-07-17 Gruenberg Micheal L. Th1 cell adoptive immunotherapy
EP1435776A4 (de) 2001-09-24 2006-01-25 Univ Pittsburgh Impfstoff gegen krebs sowie diagnoseverfahren und -reagenzien
US20030175272A1 (en) * 2002-03-07 2003-09-18 Medcell Biologics, Inc. Re-activated T-cells for adoptive immunotherapy
AU2003294220A1 (en) 2002-09-17 2004-04-23 Antigen Express, Inc. Ii-KEY/ANTIGENIC EPITOPE HYBRID PEPTIDE VACCINES
US20040072262A1 (en) 2002-10-11 2004-04-15 Montero-Julian Felix A. Methods and systems for detecting MHC class I binding peptides
CA2517108A1 (en) * 2003-02-25 2004-09-10 Tokai University Medium for stem cells in regeneration of intervertebral disc and regeneration of intervertebral disc using stem cells
EP1609107A4 (de) * 2003-03-28 2006-08-30 Idm Pharma Inc Verfahren zur identifizierung optimaler peptidepitopvarianten
WO2004094454A2 (en) 2003-04-18 2004-11-04 Idm Pharma, Inc. Hla-a2 tumor associated antigen peptides and compositions
WO2005052119A2 (en) * 2003-11-19 2005-06-09 Beth Israel Deaconess Medical Center Adjuvants of immune response
US7592431B2 (en) * 2004-02-26 2009-09-22 Immunovative Therapies, Ltd. Biodegradable T-cell Activation device
PT2573166T (pt) 2004-02-26 2016-07-07 Immunovative Therapies Ltd Métodos para preparar células-t para terapia celular
PT1749090T (pt) 2004-03-01 2017-08-28 Immunovative Therapies Ltd Formulação, método e composição para terapia celular
WO2006009838A2 (en) 2004-06-17 2006-01-26 Beckman Coulter, Inc. Mycobacterium tuberculosis epitopes and methods of use thereof
WO2007044033A2 (en) 2004-12-07 2007-04-19 University Of Pittsburgh Of The Commonwealth System Of Higher Education Therapeutic and diagnostic cloned mhc-unrestricted receptor specific for the muc1 tumor associated antigen
US7838503B2 (en) * 2005-06-15 2010-11-23 Children's Medical Center Corporation Methods for extending the replicative lifespan of cells
US8124408B2 (en) * 2006-10-04 2012-02-28 Janssen Pharmaceutica N.V. Preparation of inactivated artificial antigen presenting cells and their use in cell therapies
WO2009139921A2 (en) * 2008-05-16 2009-11-19 Genelux Corporation Microorganisms for preventing and treating neoplasms accompanying cellular therapy
US8748170B2 (en) 2008-07-25 2014-06-10 University of Pittsburgh—of the Commonwealth System of Higher Education Polypeptides derived from cyclin B1 and uses thereof
US20100310591A1 (en) * 2009-01-28 2010-12-09 Robert Humphreys Ii-KEY HYBRID PEPTIDES THAT MODULATE THE IMMUNE RESPONSE TO INFLUENZA
WO2010086294A2 (en) 2009-01-28 2010-08-05 Epimmune Inc. Pan-dr binding polypeptides and uses thereof
EP2421891A1 (de) * 2009-04-20 2012-02-29 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Immunogene epitope des ngep-antigens
DK2453914T3 (en) * 2009-07-16 2018-10-08 Vaxil Biotherapeutics Ltd ANTIGEN-SPECIFIC MULTIPLE PIT-BASED ANTI-INFECTIOUS VACCINES
US8075895B2 (en) 2009-09-22 2011-12-13 Janssen Pharmaceutica N.V. Identification of antigenic peptides from multiple myeloma cells
CA2838041C (en) 2011-05-03 2018-09-25 Immunovative Therapies, Ltd. Methods for handling biological drugs containing living cells
AU2012250807A1 (en) 2011-05-03 2013-12-12 Immunovative Therapies, Ltd. Induction of IL-12 using immunotherapy
US9844582B2 (en) 2012-05-22 2017-12-19 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-PK IL-2 and therapeutic agents
BR112016013845A2 (pt) 2013-12-19 2017-08-08 Opexa Therapeutics Inc Métodos de perfilagem de epítopos de células t, produção de composições de células t e tratamento de doenças
EP3234130B1 (de) 2014-12-19 2020-11-25 The Broad Institute, Inc. Verfahren zum profiling vom t-zell-rezeptor-repertoire
WO2018049130A1 (en) * 2016-09-09 2018-03-15 The General Hospital Corporation Ex vivo antigen-presenting cells or activated cd-positive t cells for treatment of infectious diseases
WO2018148671A1 (en) 2017-02-12 2018-08-16 Neon Therapeutics, Inc. Hla-based methods and compositions and uses thereof
EP3899954A4 (de) 2018-12-21 2022-09-14 BioNTech US Inc. Verfahren und systeme zur vorhersage von hla-klasse-ii-spezifischen epitopen und charakterisierung von cd4+-t-zellen
US20210038684A1 (en) 2019-06-11 2021-02-11 Alkermes Pharma Ireland Limited Compositions and Methods for Cancer Immunotherapy
WO2021007180A1 (en) 2019-07-05 2021-01-14 Case Western Reserve University Priming media and methods for stem cell culture and therapy
US20240150711A1 (en) 2021-03-01 2024-05-09 Dana-Farber Cancer Institute, Inc. Personalized redirection and reprogramming of t cells for precise targeting of tumors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5081029A (en) * 1985-09-25 1992-01-14 Oncogen Methods of adoptive immunotherapy for treatment of aids
US5314813A (en) * 1992-02-19 1994-05-24 Scripps Research Institute Drosophila cell lines expressing genes encoding MHC class I antigens and B2-microglobulin and capable of assembling empty complexes and methods of making said cell lines
WO1993024525A1 (en) * 1992-05-26 1993-12-09 Rijksuniversiteit Leiden PEPTIDES OF HUMAN p53 PROTEIN FOR USE IN HUMAN T CELL RESPONSE INDUCING COMPOSITIONS, AND HUMAN p53 PROTEIN-SPECIFIC CYTOTOXIC T-LYMPHOCYTES
IL109664A0 (en) * 1993-05-18 1994-08-26 Rijksuniversiteit Peptides of human influenza virus for use in human t cell response inducing compositions

Also Published As

Publication number Publication date
EP0726941A4 (de) 1999-06-16
WO1995004817A1 (en) 1995-02-16
AU7478394A (en) 1995-02-28
SG49113A1 (en) 1998-05-18
EP0726941B1 (de) 2002-04-03
EP0726941A1 (de) 1996-08-21
US5846827A (en) 1998-12-08
DE69430315T2 (de) 2002-11-21
CA2168950A1 (en) 1995-02-16

Similar Documents

Publication Publication Date Title
DE69430315D1 (de) Methoden zur (ex vivo) therapie mittels peptid - bestueckten antigen - praesentierenden zellen zur aktivierung von ctl
DE69829858D1 (de) System zum verankern von gewebe an knochen
DE69929182D1 (de) Medizinische vorrichtung zur bergung von abgetrennten organteilen mittels schlingen
DE3855891D1 (de) Gerät zur Behandlung mittels Zentrifugieren
DE69520099D1 (de) Spülverfahren mittels peressigsäure
DE69830087D1 (de) Gerät zur therapeutischen Kauterisation von vorbestimmten Volumen biologischen Gewebes
DE60039824D1 (de) Vorrichtung zur Behandlung von biologischen Geweben mittels Elektrizität oder Medikamenten
AU3393993A (en) Method of administering proteins to living skin cells
DK90888A (da) Maaleapparat til vaevsmetabolisme
DE69325256D1 (de) Insizierbare lecithin gel
HK34090A (en) Apparatus for treatment of living tissue by stimulation by means of pulses of electric current and/or by means of electro-magnetic waves
DK333788A (da) Farmaceutisk praeparat til behandling af oedelagt bruskvaev
DE69731232D1 (de) Vorrichtung zur behandlung von pathologischen zuständen mittels elektromagnetischer hautstimulation
DE68918144D1 (de) System zur Belichtung mittels geladener Teilchenstrahlen.
NO870772D0 (no) Vevplasminogenaktivator for normale humane tykktarmceller.
DE69534180D1 (de) Promotor der tie rezeptor protein kinase
IT1299175B1 (it) Composizione contenente radioisotopi immobilizzati su particelle solide, utile in particolare per la brachiterapia clinica in patologie
DK0951553T3 (da) Adenovirus-E4-proteiner til induktion af celledød
DE69713570D1 (de) Verfahren zum abtöten neoplastischer zellen mittels piperazin-oxiran derivaten
DK410887D0 (da) Protein isoleret fra pattedyrhjernevaev
DE69519219D1 (de) Verwendung von (2S,4S)-6-fluoro-2',5'-dioxospiro[chroman-4,4'-imidazoline]-2-carboxamid zur Behandlung von Keratopathie
DE69521281D1 (de) Verfahren zur Herstellung von menschlichem oder humanem Matrilysin mittels rekombinanter DNA.
EP0099057A3 (en) N-acyl derivatives of peptides, their manufacture and use in combating diseases and means therefor
IT8967876A0 (it) Piastra chirurgica di supporto per organi umani
NO891096D0 (no) Fremgangsmaate for ekspresjon under stimulering fra et induserbart uttrykt aktivatorprotein.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition